SNDX News and Press, Syndax Pharmaceuticals Inc. From 05/08/23

2023-05-08 22:53:03 ET Syndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Conference Call May 08, 2023, 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President and Head of R&...

2023-05-08 16:13:37 ET Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q1 GAAP EPS of -$0.59 beats by $0.01 . As of March 31, 2023, Syndax had cash, cash equivalents, short- and long-term investments of $449.0 million and 69.6 million common shares and pr...

Syndax Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update PR Newswire – Topline data from the pivotal AGAVE-201 trial of axatilimab in cGVHD on track for mid-2023 – – Topline data from the pivotal...

Syndax to Announce First Quarter 2023 Financial Results and Host Conference Call and Webcast on May 8, 2023 PR Newswire WALTHAM, Mass. , May 1, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company devel...

Syndax Pharmaceuticals Announces Appointment of Neil Gallagher, M.D., Ph.D. as President, Head of Research and Development PR Newswire - Neil Gallagher , M.D., Ph.D. brings to Syndax over 20 years of experience as a leading oncology drug developer - WALTH...

Syndax Pharmaceuticals Announces Two Publications in Nature of Data from the Phase 1 Portion of AUGMENT-101 in Acute Leukemia Patients PR Newswire WALTHAM, Mass. , March 15, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) today announced tha...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass. , March 6, 2023 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative ...

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Results Conference Call February 28, 2023 04:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Dr. Briggs Morrison - President and Head, R&D Keith Goldan ...

Summary Syndax Pharmaceuticals, Inc. has two pivotal trials with data readouts coming up in 2023, with possible regulatory filings. They are loaded with cash after a successful offering. Despite current highs, I see further upside in 2023. Syndax Pharmaceuticals, Inc. ( ...

Syndax Pharmaceuticals press release ( NASDAQ: SNDX ): Q4 GAAP EPS of -$0.62 beats by $0.04 . As of December 31, 2022, Syndax had cash, cash equivalents, short-term and long-term investments of $481.3 million and 69.3 million common shares and prefunded warrants outstandi...